MetaCap

GRAIL Inc. (GRAL)

NASDAQ: GRALHealth CareMedical SpecialitiesUSD

99.25-5.59 (-5.33%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

GRAL stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$9.22
52-week range
41.50 – 166.48
Day range
98.36 – 103.96
Volume / Avg
757.79K / 1.03M
Beta
—

52-week range

$41.50$166.48

GRAL stock today

On Nov 20, GRAL ended the session at $99.25, shedding $5.59 (5.33%), versus the S&P 500's 3.70% decline. At this level, GRAL sits in the middle of its 52-week range of $41.50 to $166.48: 40.4% below the high, set on Oct 6, 2026 and 139.2% above the low. GRAL is up 16.0% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 6.1%.

GRAIL has posted a net loss over the last twelve months (EPS of -$9.22), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About GRAIL

Company profile

GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development.

Industry
Medical Specialities
CEO
Dr. Joshua J. Ofman M.D., M.S.H.S
Headquarters
Sunnyvale, CA
Employees
910
Website
grail.com

Financial highlights

Full financials

In fiscal 2025, GRAIL generated $147.2 million in revenue, up 17.2% from fiscal 2024, its 3rd consecutive year of revenue growth. GRAIL reported a net loss of $408.4 million, compared with a loss of $2.03 billion a year earlier. Operating margin was -382.0%.

GRAIL annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2023
Revenue$147.17M$125.59M$93.11M$55.55M
Growth+17.18%+34.90%+67.61%—
Net income$-408.35M$-2.03B$-1.47B$-5.40B
EPS (diluted)$-11.11$-63.54$-47.21$-173.89

Analyst forecast

Forecast

Consensus (10 analysts)

buy

Avg. price target

$139.44+40.49%

  • Strong buy 0
  • Buy 5
  • Hold 5
  • Sell 0
  • Strong sell 0

Target range

Low $100.00High $175.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 4, 2026
EPS actual vs est.
$-2.46 vs $-2.78
Surprise
+11.51%

GRAL news

All GRAL news

GRAIL peers

Health Care sector
GRAL peer companies
CompanyPrice% ChgMarket capCompare
BLLNBillionToOne Inc. Class A89.92-0.31%$4.30Bvs GRAL
CAICaris Life Sciences Inc.17.58-5.18%$5.04Bvs GRAL
CDNACareDx Inc.70.00-2.67%$3.68Bvs GRAL
CONConcentra Group Holdings Parent Inc.41.84+0.94%$5.26Bvs GRAL
RDNTRadNet Inc.69.71+0.29%$5.49Bvs GRAL
ACHCAcadia Healthcare Company Inc.34.60+0.38%$3.22Bvs GRAL
CELCCelcuity Inc.53.35-5.26%$2.61Bvs GRAL
VCYTVeracyte Inc.25.13+0.36%$2.03Bvs GRAL

Indexes, lists and sector

GRAIL stock FAQ

What is GRAIL's stock price today?

GRAL last traded at $99.25 as of Nov 20, 4:00 PM EST, down 5.33% on the day. Prices are delayed at least 15 minutes.

Who is GRAIL's CEO?

Dr. Joshua J. Ofman M.D., M.S.H.S is the chief executive officer of GRAIL Inc., which has about 910 employees.

What is the GRAL 52-week high?

The 52-week high for GRAL is $166.48 and the 52-week low is $41.50. The stock is currently 40.4% below its high.

Compare GRAL